Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Nutrients. 2023 Aug 25;15(17):3733. doi: 10.3390/nu15173733.
Νon-alcoholic fatty liver disease (NAFLD) is a common cause of end-stage liver disease in developed countries. Oxidative stress plays a key role during the course of the disease and vitamin E supplementation has shown to be beneficial due to its antioxidative properties. We aim to investigate the effect of vitamin E supplementation on serum aminotransferase levels in patients with NAFLD. Three electronic databases (MEDLINE, CENTRAL, and Embase) were reviewed for randomized trials that tested vitamin E supplementation versus placebo or no intervention in patients with NAFLD, published until April 2023. A total of 794 patients from 12 randomized trials were included in this meta-analysis. Notwithstanding the studies' heterogeneity and moderate internal validity in certain cases, among studies testing vitamin E supplementation at 400 IU/day and above, the values of alanine aminotransferase (ALT) were reduced compared with placebo or no intervention [ALT Mean Difference (MD) = -6.99 IU/L, 95% CI (-9.63, -4.35), for studies conducted in Asian countries and MD = -9.57 IU/L, 95% CI (-12.20, -6.95) in non-Asian countries]. Regarding aspartate aminotransferase (AST), patients in the experimental group experienced a reduction in serum levels, though smaller in absolute values [AST MD = -4.65 IU/L, 95% CI (-7.44, -1.86) in studies conducted in Asian populations] and of lower precision in non-Asian studies [MD = -5.60 IU/L, 95% CI (-11.48, 0.28)].
非酒精性脂肪性肝病 (NAFLD) 是发达国家终末期肝病的常见病因。氧化应激在疾病过程中起着关键作用，维生素 E 补充因其抗氧化特性已被证明是有益的。我们旨在研究维生素 E 补充对 NAFLD 患者血清氨基转移酶水平的影响。我们对 MEDLINE、CENTRAL 和 Embase 这三个电子数据库进行了综述，以寻找测试维生素 E 补充剂与安慰剂或无干预措施在 NAFLD 患者中的随机试验，检索时间截至 2023 年 4 月。共有来自 12 项随机试验的 794 名患者纳入本荟萃分析。尽管这些研究存在异质性和某些情况下的内部有效性中等，但在测试 400IU/天及以上剂量的维生素 E 补充剂的研究中，与安慰剂或无干预相比，丙氨酸氨基转移酶 (ALT) 的值降低 [ALT 平均差值 (MD) = -6.99IU/L，95%置信区间 (-9.63, -4.35)，针对在亚洲国家进行的研究；MD = -9.57IU/L，95%置信区间 (-12.20, -6.95)，针对在非亚洲国家进行的研究]。关于天冬氨酸氨基转移酶 (AST)，实验组患者血清水平降低，但绝对值较小 [AST MD = -4.65IU/L，95%置信区间 (-7.44, -1.86)，针对在亚洲人群中进行的研究]，且在非亚洲研究中精确度较低 [MD = -5.60IU/L，95%置信区间 (-11.48, 0.28)]。
